Uptake, accumulation, and translocation mechanisms of steroid estrogens in plants

Xingcai Chen,Yanxia Li,Linshu Jiang,Baiyang Hu,Lin Wang,Siyu An,Xuelian Zhang

DOI: https://doi.org/10.1016/j.scitotenv.2020.141979

2021-01-01

Abstract:Applying sewage sludge or animal manure onto agricultural land can result in estrogen pollution, which increases the risk of human exposure to steroid estrogens (SEs) via the food chain. However, the uptake and accumulation mechanism of SEs by plants is still unclear. In this study, the uptake, accumulation, and translocation of 17β-E2, a representative SE, were investigated through a series of wheat hydroponic experiments. Various inhibitors were applied to explore the uptake pathways of 17β-E2 by wheat. In addition, the effects of exposure concentrations, coexisting 17α-ethynylestradiol (EE2) and plant properties on the uptake of 17β-E2 were examined. The results indicated that the accumulation of 17β-E2 in wheat roots mainly resulted from adsorption and active uptake that involved aquaporins and anion channels transport. The chlorophyll and protein contents of plants were positively correlated with the uptake of 17β-E2, whereas competitive inhibition occurred when 17β-E2 and EE2 coexisted in the same solution. Nevertheless, the results of a split-root experiment showed that 17β-E2 absorbed by wheat could further migrate in plant via long-distance transport and ultimately was discharged from plants, suggesting that 17β-E2 was still at risk of being released even though it had been absorbed by plants. These results could provide valuable insights into the risk assessment and risk control of the uptake of SEs by plants.

environmental sciences

What problem does this paper attempt to address?

### Problems the Papers Try to Solve

#### Paper 1: Gene Targeting and Gene Correction
**Problem Background**:
Spinal Muscular Atrophy (SMA) is a neurodegenerative disease caused by mutations in the SMN1 gene. SMA patients usually carry one or more copies of the SMN2 gene, and these genes produce less functional protein due to abnormal splicing. Currently, treatment methods for SMA are limited, so new treatment strategies need to be developed.

**Research Objectives**:
This paper aims to correct the abnormal splicing of the SMN2 gene by using the Non - Homologous End - Joining (NHEJ) pathway, thereby restoring the expression of SMN protein in SMA patient cells. Specifically, the researchers used the CRISPR/Cas9 system to verify the effectiveness of this method in vitro experiments.

**Main Methods**:
- **Experimental Design**: A plasmid containing the Cas9 - GFP fusion protein was constructed, and specific gRNA sequences were selected to target the splicing site of the SMN2 gene.
- **Cell Lines**: The HEK - 293T cell line and immortalized myoblasts from healthy donors and SMA patients were used for transfection experiments.
- **Detection Methods**: Transfection efficiency was evaluated by fluorescence microscopy, nuclease activity was detected by Surveyor assay and target - site sequencing, and the restoration of SMN protein was analyzed by qPCR and Western Blot.

**Expected Results**:
- **Gene Editing Effect**: In myoblasts derived from SMA patients, insertions or deletions (indels) were detected at approximately 30% of the induced DNA double - strand breaks.
- **SMN Protein Restoration**: The restoration of SMN protein was further verified by qPCR and Western Blot.

**Research Significance**:
This study provides an in vitro proof - of - principle for effective gene correction in SMA patient cells. For complex multi - system diseases such as SMA, targeted gene - editing strategies may become a new treatment tool.

#### Paper 2: Gene Therapy of Autosomal Dominant Retinitis Pigmentosa with Self - Complementary Recombinant Adeno - Associated Virus
**Problem Background**:
Retinitis Pigmentosa (RP) is the main cause of hereditary blindness, and 30 - 40% of cases are caused by Autosomal Dominant Retinitis Pigmentosa (ADRP). The causes of ADRP are diverse, and at least 24 known genes are associated with it, and 30% of cases are related to mutations in the rhodopsin gene (RHO). Due to the heterogeneity of RHO gene mutations, traditional gene - therapy strategies are difficult to deal with effectively.

**Research Objectives**:
This paper proposes a new gene - therapy method, that is, by knocking down the endogenous RHO gene and replacing it with a "hardened" RHO gene to reduce the efficiency of gene knockdown. The researchers used self - complementary recombinant adeno - associated virus (scAAV) vectors to express the hardened human rhodopsin (hRHO) and shRNA to achieve this goal.

**Main Methods**:
- **Knockdown Methods**: Four different knockdown methods (ribozymes Rz407 and Rz525, miRNA 301 and shRNA 301) were tested, targeting the wild - type and hardened RHO target regions respectively.
- **Cell Experiments**: Transfection experiments were carried out in HEK293 cells, and the knockdown effect was evaluated by the dual - luciferase reporter system.
- **Animal Experiments**: The scAAV vector was used to deliver the hardened human rhodopsin and knockdown agents to mouse models of Rho I307N and human RHO transgenic T17M and P23H, and the treatment effect was evaluated by electrophysiology and optical coherence tomography (OCT).

**Expected Results**:
- **Knockdown Effect**: shRNA301 and ribozyme 525 are the most effective in reducing RHO mRNA levels.
- **Animal Experiments**: In the eyes of T17M RHO mice injected with scAAV - hRHO - shRNA750, there was a significant difference in visual function compared with the control group one month later.

**Research Significance**